PubMed Health⌕ Search

PubMed · 12766311

[Three-dimensional conformal radiotherapy with multi-leaf collimator]

Abstract

In radiation therapy, it is very important to concentrate the high dose to the clinical target volume. For this purpose, S. Takahashi developed the dynamic conformal radiotherapy in 1960. In the first half of 1990' this conformal technique with multi-leaf collimator (MLC) was gradually becoming popular, because the three dimensional extent of the clinical target volume and the surrounding normal tissues was accurately recognized by the use of the serial CT-images, and the 3D-treatment planning was considerably easily obtained by the development of computer-technique. The 3D-CRT (conformal radiation therapy) based on the 3D-treatment planning in a broad sense means the coplanar or non-coplanar irradiation with multi-leaf collimator, and at present it is one of the most reasonable treatment techniques. In order to correspond the high dose region to the clinical target volume as possible, IM (intensity modulation) technique was introduced to the 3D-CRT using MLC in the second half of 1990'. Therefore, the static CRT is routinely used not only in Europe/ USA but also in Japan. But, it is often very difficult to obtain the concave high dose region in static CRT with MLC, even though the IM-technique is applied. At this occasion, the concave high dose region is easily obtained by the use of dynamic CRT such as the hollowed -out technique developed by S. Takahashi in Japan. The dynamic CRT technique is also useful with the static IM-CRT technique. There are two main aims of conformal radiotherapy: First, the protection of the surrounding normal tissues, and second, improvement of the local control rate. Usually the second aim can't be easily achieved, because the tumor control probability curves are often flat. The DVH concept is usually valuable to choose the optimal treatment planning. But, it is difficult to find the optimal dose-distribution, when two DVH-curves cross each other on the middle range of irradiated dose. On that occasion, the NTCP-concept is useful. From the standpoint of the tolerable dose, normal organs are classified into two types: parallel and serial. Therefore, two types of the NTCP-formula should be prepared to apply the NTCP-concept clinically.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yukio Uchiyama, Kozo Morita. 2001. [Three-dimensional conformal radiotherapy with multi-leaf collimator]. https://pubmed.ncbi.nlm.nih.gov/12766311/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗